| Trial ID: | L1261 |
| Source ID: | NCT01046955
|
| Associated Drug: |
Anti-Thymocyte Globulin Vs Campath-1h Vs Daclizumab
|
| Title: |
Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End-Stage Renal Disease|Living Donors
|
| Interventions: |
DRUG: Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab
|
| Outcome Measures: |
Primary: To observe in a randomized prospective pilot study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor kidneys., 3 years|Patient/graft survival., 1 and 3 yrs. | Secondary: Incidence of adverse reactions., 1 & 3 years.
|
| Sponsor/Collaborators: |
Sponsor: University of Miami | Collaborators: Hoffmann-La Roche
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
38
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose:
|
| Start Date: |
2005-11
|
| Completion Date: |
2008-12
|
| Results First Posted: |
|
| Last Update Posted: |
2010-01-12
|
| Locations: |
University of Miami Jackson Memorial Hospital, Miami, Florida, 33136, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01046955
|
